Cocrystal Pharma
Cocrystal Pharma is a clinical-stage biotechnology company specializing in the discovery and development of novel antiviral therapeutics for serious and chronic viral diseases such as influenza, COVID-19, hepatitis C, norovirus, and other respiratory viruses. The company leverages structure-based drug discovery technology and expertise in structural biology to design direct viral replication inhibitors with broad-spectrum activity. Its pipeline includes candidates in preclinical and clinical development, addressing unmet needs in antiviral medicine.
Industries
N/A
Cocrystal Pharma
19805 North Creek Parkway, Bothell, WA 98011
Patents
Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication
2025-07-15 • US-12357631-B2
View DetailsPyridopyrazine and pyridotriazine inhibitors of influenza virus replication
2024-07-16 • US-12037333-B2
View Details
Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication
2025-07-15 • US-12357631-B2
View DetailsPyridopyrazine and pyridotriazine inhibitors of influenza virus replication
2024-07-16 • US-12037333-B2
View DetailsProducts
An oral small molecule protease inhibitor in clinical development for prevention and treatment of norovirus and coronavirus infections, designed to target highly conserved viral proteases.
Oral small molecule PB2 inhibitor targeting the influenza polymerase complex for treatment of pandemic and seasonal influenza A, with completion of Phase 2a studies.
Inhaled formulation of influenza A PB2 inhibitor shown to deliver drug effectively to the lung with supportive safety and toxicology data.
Small molecule inhibitor developed to target HCV NS5B polymerase for use in ultra-short duration combination regimens for hepatitis C with demonstrated efficacy and safety in Phase 2a studies.
Protease inhibitor in preclinical development to address rhinovirus infections and other respiratory viruses.
Oral replication inhibitor in preclinical development designed for activity across influenza A and B strains.
An oral small molecule protease inhibitor in clinical development for prevention and treatment of norovirus and coronavirus infections, designed to target highly conserved viral proteases.
Oral small molecule PB2 inhibitor targeting the influenza polymerase complex for treatment of pandemic and seasonal influenza A, with completion of Phase 2a studies.
Inhaled formulation of influenza A PB2 inhibitor shown to deliver drug effectively to the lung with supportive safety and toxicology data.
Small molecule inhibitor developed to target HCV NS5B polymerase for use in ultra-short duration combination regimens for hepatitis C with demonstrated efficacy and safety in Phase 2a studies.
Protease inhibitor in preclinical development to address rhinovirus infections and other respiratory viruses.
Oral replication inhibitor in preclinical development designed for activity across influenza A and B strains.
Expertise Areas
- Antiviral drug development
- Structure-based drug design
- Small molecule therapeutics
- Pan-viral inhibitor discovery
Key Technologies
- Structure-based drug discovery
- X-ray crystallography
- Protein-inhibitor complex analysis
- Preclinical in vitro and in vivo modeling
Key People
Chief Executive Officer
President and Chief Scientific Officer
Chief Financial Officer
Chairman of the Board and Chief Scientist
Vice Chairman
Director
Chief Executive Officer
President and Chief Scientific Officer
Chief Financial Officer
Chairman of the Board and Chief Scientist
Vice Chairman
Director
News & Updates
Chairman and key scientific advisor awarded Nobel Prize for studies of the molecular basis of eukaryotic transcription, underpinning the structure-based platform.
Discussion of preclinical and clinical strategy for norovirus antivirals.
Interview focused on development of broad-spectrum antivirals and implications of emerging influenza threats.
Analysis of structure-based technologies for antiviral discovery.
Overview of preclinical and early clinical results from an oral protease inhibitor for norovirus.
Coverage of development pipeline progress in multiple antiviral programs.
Chairman and key scientific advisor awarded Nobel Prize for studies of the molecular basis of eukaryotic transcription, underpinning the structure-based platform.
Discussion of preclinical and clinical strategy for norovirus antivirals.
Interview focused on development of broad-spectrum antivirals and implications of emerging influenza threats.
Analysis of structure-based technologies for antiviral discovery.
Overview of preclinical and early clinical results from an oral protease inhibitor for norovirus.
Coverage of development pipeline progress in multiple antiviral programs.